DDX5 helicase resolves G-quadruplex and is involved in MYC gene transcriptional activation
Significance
G-quadruplexes (G4) are 4-stranded nucleic acid secondary structures. MYC is a critical oncogene with a G4 in its promoter (MycG4), which acts as a transcription silencer. MycG4 is very stable and the pathological activation of MYC in cancers requires its active unfolding. We reveal herein that DDX5, a founding member of the DEAD-box RNA helicase family, can unfold DNA G4s. The unfolding mechanism of DDX5 is distinct from previously characterized G4 helicases. Importantly, DDX5 activates MYC gene transcription by proficiently unfolding the promoter MycG4. DDX5 is overexpressed in cancers and the DDX5–MycG4 interaction can be inhibited by small molecules to downregulate MYC . Therefore, our results suggest a new molecular target to suppress MYC for cancer intervention.
Top-30
Journals
|
1
2
3
4
5
6
7
|
|
|
Nucleic Acids Research
7 publications, 6.25%
|
|
|
Molecules
5 publications, 4.46%
|
|
|
Journal of the American Chemical Society
5 publications, 4.46%
|
|
|
International Journal of Molecular Sciences
4 publications, 3.57%
|
|
|
Biochemical and Biophysical Research Communications
4 publications, 3.57%
|
|
|
Genes
3 publications, 2.68%
|
|
|
Nature Communications
3 publications, 2.68%
|
|
|
Journal of Biological Chemistry
3 publications, 2.68%
|
|
|
Communications Biology
2 publications, 1.79%
|
|
|
Computational and Structural Biotechnology Journal
2 publications, 1.79%
|
|
|
Methods
2 publications, 1.79%
|
|
|
International Journal of Biological Macromolecules
2 publications, 1.79%
|
|
|
iScience
2 publications, 1.79%
|
|
|
Journal of Medicinal Chemistry
2 publications, 1.79%
|
|
|
Life Science Alliance
2 publications, 1.79%
|
|
|
Bioengineered
2 publications, 1.79%
|
|
|
Journal of Biochemistry
2 publications, 1.79%
|
|
|
Biological Chemistry
2 publications, 1.79%
|
|
|
bioRxiv
2 publications, 1.79%
|
|
|
Frontiers in Cell and Developmental Biology
2 publications, 1.79%
|
|
|
Biochemistry and Cell Biology
1 publication, 0.89%
|
|
|
Cancers
1 publication, 0.89%
|
|
|
Frontiers in Molecular Biosciences
1 publication, 0.89%
|
|
|
Frontiers in Oncology
1 publication, 0.89%
|
|
|
Signal Transduction and Targeted Therapy
1 publication, 0.89%
|
|
|
Cell Death Discovery
1 publication, 0.89%
|
|
|
Nature Reviews Genetics
1 publication, 0.89%
|
|
|
Journal of Controlled Release
1 publication, 0.89%
|
|
|
Analytical and Bioanalytical Chemistry
1 publication, 0.89%
|
|
|
1
2
3
4
5
6
7
|
Publishers
|
5
10
15
20
25
30
|
|
|
Elsevier
26 publications, 23.21%
|
|
|
MDPI
14 publications, 12.5%
|
|
|
Springer Nature
12 publications, 10.71%
|
|
|
Oxford University Press
11 publications, 9.82%
|
|
|
Cold Spring Harbor Laboratory
11 publications, 9.82%
|
|
|
American Chemical Society (ACS)
10 publications, 8.93%
|
|
|
Frontiers Media S.A.
5 publications, 4.46%
|
|
|
Taylor & Francis
3 publications, 2.68%
|
|
|
American Society for Biochemistry and Molecular Biology
2 publications, 1.79%
|
|
|
Rockefeller University Press
2 publications, 1.79%
|
|
|
Walter de Gruyter
2 publications, 1.79%
|
|
|
Wiley
2 publications, 1.79%
|
|
|
Canadian Science Publishing
1 publication, 0.89%
|
|
|
Public Library of Science (PLoS)
1 publication, 0.89%
|
|
|
Pleiades Publishing
1 publication, 0.89%
|
|
|
BMJ
1 publication, 0.89%
|
|
|
American Association for Cancer Research (AACR)
1 publication, 0.89%
|
|
|
IOP Publishing
1 publication, 0.89%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 0.89%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.89%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.89%
|
|
|
5
10
15
20
25
30
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.